Related Experiment Video

Updated: Jul 4, 2026

Evaluating Cell Death Signaling by Immunofluorescence in a Rat Model of Ischemic Stroke
11:32

Evaluating Cell Death Signaling by Immunofluorescence in a Rat Model of Ischemic Stroke

Published on: January 3, 2025

HDL-C and LDL-C: their role in stroke pathogenesis and implications for treatment

Nerses Sanossian1, Nicholas E Tarlov

  • 1Department of Neurology, University of Southern California, LAC+USC Medical Center, 1200 North State Street, Room 5640, Los Angeles, CA 90033, USA. sanossia@yahoo.com

Current Treatment Options in Cardiovascular Medicine
|June 28, 2008
PubMed

Insights

High LDL cholesterol and low HDL cholesterol increase stroke risk. Guidelines recommend statins for LDL reduction and niacin or fibrates for HDL improvement in stroke prevention.

Area of Science:

  • Cardiovascular Medicine
  • Neurology
  • Endocrinology

Background:

  • Elevated low-density lipoprotein cholesterol (LDL-C) and low high-density lipoprotein cholesterol (HDL-C) are established risk factors for atherosclerotic ischemic stroke.
  • Dyslipidemia management is crucial for preventing cerebrovascular events.

Purpose of the Study:

  • To outline current guidelines for dyslipidemia treatment in the context of stroke prevention.
  • To emphasize the importance of targeting both LDL-C and HDL-C levels.

Main Methods:

  • Review of National Cholesterol Education Panel and American Heart Association guidelines.
  • Discussion of pharmacologic interventions for dyslipidemia, including statins, extended-release niacin, and fibrates.

Main Results:

  • Guidelines prioritize LDL-C reduction using HMG CoA reductase inhibitors (statins).
  • Treatment of low HDL-C is a secondary goal, effectively managed with extended-release niacin and fibrates, alone or in combination with statins.

Conclusions:

  • Early and aggressive management of dyslipidemia is a key component of a comprehensive stroke prevention strategy.
  • A multimodality approach incorporating lipid-lowering therapies is essential for reducing atherosclerotic ischemic stroke risk.

Related Concept Videos

Ischemic Stroke ll: Pathophysiology01:15

Ischemic Stroke ll: Pathophysiology

An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...
Ischemic Stroke l: Introduction01:15

Ischemic Stroke l: Introduction

Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.
Hemorrhagic Stroke ll: Pathophysiology01:29

Hemorrhagic Stroke ll: Pathophysiology

A hemorrhagic stroke develops when a cerebral blood vessel ruptures, allowing blood to escape into the surrounding brain tissue, as in intracerebral hemorrhage (ICH), or into the subarachnoid space, as in subarachnoid hemorrhage (SAH). Because the skull is a rigid compartment, the sudden presence of extravascular blood rapidly increases intracranial pressure and compresses adjacent neural structures, leading to immediate tissue injury and impaired cerebral perfusion.Mass Effect and Primary...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...